Loading...
Market
In which condition will Eli Lilly's genetic medicine center make significant progress by the end of 2024?
2
Resolution / Starting Odds
Diabetes • 25%
Obesity • 25%
Heart Disease • 25%
Chronic Pain • 25%
Official announcements from Eli Lilly or reputable news sources
Story
Eli Lilly Opens $700 Million Genetic Medicine Center in Fort Point, Boston
Aug 13, 2024, 01:14 PM
Eli Lilly has inaugurated a new $700 million center for genetic medicine in Fort Point, Boston Seaport. The facility will focus on RNA- and DNA-based drugs and novel treatments for conditions such as diabetes, obesity, heart disease, and chronic pain. Over 200 employees have relocated from Cambridge to the new research and development center, which will also house a biotech incubator for startups. The company plans to hire an additional 300 employees, bringing the total workforce in Boston to 500. Eli Lilly's investment in genetic medicine includes the acquisition of Prevail Therapeutics for approximately $1.5 billion in 2020 and Akouos for $487 million in 2022.
View original story
Similar markets
Proof-of-concept data achieved • 25%
Partnership announcement • 25%
Regulatory approval submission • 25%
No major milestone achieved • 25%
Cardiovascular • 25%
Oncology • 25%
Neurology • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
0 to 2 • 25%
3 to 5 • 25%
6 to 8 • 25%
More than 8 • 25%
Yes • 50%
No • 50%
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Data Released • 25%
